Introduction to sevelamer hydrochloride and its clinical effects

Therapeutic Apheresis and Dialysis

Volumn 9, Issue SUPPL. 1, 2005, Pages

  Tahara, Hideki ^a   Tsujimoto, Yoshihiro ^b   Shoji, Tetsuo ^a   Inaba, Masaaki ^a   Tabata, Tsutomu ^b   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Inoue Hospital   (Japan)

Author keywords

K DOQI guidelines; Non HDL C; Sevelamer hydrochloride

Indexed keywords

CALCIUM; CALCIUM CARBONATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER; POLYAMINE;

ADULT; AGED; CALCIUM METABOLISM; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SUBSTITUTION; FEMALE; HUMAN; HYPERPHOSPHATEMIA; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; ARTICLE; CHRONIC KIDNEY FAILURE; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; DRUG COMBINATION; KIDNEY FAILURE; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM; CALCIUM CARBONATE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY FAILURE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHORUS; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES; RETROSPECTIVE STUDIES;

EID: 33645269724     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2005.00279.x     Document Type: Conference Paper

References (2)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-202.
2. Nishizawa Y, Shoji T, Kakiya R et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int 2003;84:S117-20.